Treatment with Que-CH significantly reduced serum IL-1β, improved liver histology by decreasing macro- and microvesicular steatosis, and lowered the Bax/Bcl-2 ratio, indicating reduced hepatocyte apoptosis. Here, BAX is linked to steatosis.